Solid Biosciences Inc. SLDB announced that the FDA has cleared its investigational new drug (IND) application to begin ...
Kymera Therapeutics, Inc. KYMR announced that its investigational New Drug (IND) application for pipeline candidate, KT-621, has been cleared by the FDA. KT-621 is an investigational first-in ...
Principal Investigators on treatment protocols that involve an Investigational New Drug (IND ... of FDA-regulated studies using investigational drugs or biologics (i.e., agents that require an IND ...
The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...
is pleased to announce the filing of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead candidate, NUZ-001. This milestone is a pivotal step ...
The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...
has cleared the Company’s Investigational New Drug (IND) application for MF-300, a first-in-class orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in ...
Tyra Biosciences (TYRA) announced that the U.S. FDA cleared its Investigational New Drug application for TYRA-300 allowing the company to ...
has announced the filing of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its lead candidate, NUZ-001. This milestone is a pivotal step in enabling the ...
SGT-212 is the company's novel, AAV-based FA gene therapy candidate designed to deliver full-length frataxin via systemic intravenous (IV) infusion as well as direct intradentate nuclei (IDN) infusion ...
The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...
Please provide your email address to receive an email when new articles are posted on . A phase 1/2 trial will assess safety, tolerability and preliminary efficacy for VG801. The FDA also selected ...